Dr. Eddy Littler
Chief Operating Officer
Eddy began his research career at the University of Leeds studying herpesvirus DNA replication. After postdoctoral research at McMaster University in Canada, he joined the Paterson Institute for Cancer Research in Manchester. Here Eddy investigated viruses and cancer including Epstein-Barr virus and Human Herpesvirus type 6. After six successful years, he joined the Wellcome Research Laboratories as Head of Herpes Virus Research. During his time at Wellcome, he became Head of the Gene Targets Group which had projects in herpesviruses, respiratory viruses, including RSV, and gene therapy of ovarian cancer. Following the acquisition of Wellcome by Glaxo he became Head of Antiviral Research at GlaxoWellcome leading teams working on hepatitis C virus, influenza virus, and respiratory syncytial virus.
Eddy left GSK in 2000 to join Medivir as Senior Director of Lead Discovery and Head of UK Operations. While at Medivir he played a significant role in several deals, including the development and eventual out-licensing of the HCV protease inhibitor (Simeprevir) programme to Tibotec (J&J). The total value of transactions converted at Medivir was $360M.
Eddy became the Chief Executive Officer of Domainex in May 2008. He developed Domainex to become one of the UK’s leading drug discovery CROs. Under his leadership, Domainex also developed a pipeline of drugs aimed at inflammation and cancer.
In October 2016 Eddy joined ReViral, initially as CEO, then as COO from June 2019 as the Company moved into Phase 2 development.